US SEC Trading Suspension Halt Orders — October 15, 2026

Stock closed below $1.00 for 30 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) notice dated October 9, 2026; cure deadline April 7, 2027

Stock closed below $1.00 for 30 consecutive business days, triggering Nasdaq notice dated October 14, 2026; cure deadline April 12, 2027, with no assurance of regaining compliance per company statement

Company states it will closely monitor the bid price and consider all options including a reverse stock split, signaling management is preparing a potential dilutive or capital-structure action

Company explicitly disclaims assurance of cure, a notably cautious posture that increases the probability of a reverse split or extended compliance request

Notice does not trigger immediate suspension, so trading continues and the near-term liquidity impact is limited while the 180-day clock runs

Eligibility for a second 180-day period depends on meeting market value of publicly held shares and other initial listing standards, a conditional path that is worth monitoring as an alternative to a reverse split

Failure to close at or above $1.00 for 10 consecutive business days by April 7, 2027 leads to delisting notice unless a second 180-day period is granted; second period requires meeting initial listing criteria except bid price and committing to a reverse split if needed

Failure to regain compliance by April 12, 2027 could initiate delisting proceedings; additional time requires meeting market value of publicly held shares and other listing standards, plus written notice of intent to cure

Reverse stock split is explicitly under consideration, which typically reduces share count without adding value and can precede weak post-split trading

Written notice of intent to cure may require a reverse stock split, a likely near-term corporate action with potential shareholder approval requirements

Ticker LUCYW indicates listed warrants are also subject to the same listing regime, so warrant holders face parallel delisting risk

If delisting is issued, a Nasdaq Hearings Panel request would stay suspension, but the process adds time and uncertainty before any resolution

Announcement of a reverse split with a defined ratio and effective date could create a tradable event; post-split stock must hold above $1.00 for 10 days to cure, so event-driven positioning around the split date is the key window

Stock must close at or above $1.00 for 10 consecutive business days before April 12, 2027, so a sustained price recovery would resolve the notice well before the deadline and could re-rate the equity

If the company qualifies for the additional 180 days, the extended runway reduces forced-selling pressure from institutional mandates tied to listing status

A Nasdaq Hearings Panel request stays suspension pending review, giving the company a defined procedural path to preserve listing and buy time if fundamentals improve

Both names fall into a recognizable Nasdaq deficiency cohort with defined April 2027 deadlines, creating a catalyst calendar for event-driven and special-situation desks to track

Two small-cap issuers received bid price deficiency notices within a single 6-day window (October 9 and October 14, 2026), both with cure deadlines in April 2027, suggesting a concentrated pressure point among micro-cap Nasdaq listings tied to the same 30-day closing-price test

Both filings reference a potential reverse stock split as the primary cure mechanism, indicating that for sub-$1 issuers the standard remediation path is capital-structure action rather than operating recovery, with implications for post-split price performance and shareholder dilution

Both companies depend on eligibility for a second 180-day period, which requires meeting initial listing standards other than bid price; the common dependency means many similar issuers may face a binary outcome between cure and delisting in 2027

Reverse stock split announcement and any shareholder meeting notice; compliance deadline April 7, 2027 and daily closing price versus $1.00 threshold

Written notice of intent to cure and any reverse split proposal; compliance deadline April 12, 2027 and eligibility for second 180-day period

Parallel listing status and any warrant adjustment terms tied to a reverse split

Any request for hearing or delisting determination letter, which would change suspension status and timeline

Consecutive closing-day count above or below $1.00, since a 10-day streak is required to cure and interruptions reset the cure clock